Journal
EUROPEAN JOURNAL OF IMMUNOLOGY
Volume 52, Issue 4, Pages 656-668Publisher
WILEY
DOI: 10.1002/eji.202149523
Keywords
autoimmunity; B cells; neuroimmunology
Categories
Funding
- Projekt DEAL
Ask authors/readers for more resources
B-cell modulation through targeting CD79b can achieve therapeutic effects in autoimmune diseases like MS, offering an alternative approach to complete B-cell depletion with anti-CD20 antibodies.
B cells play a major role in the pathogenesis of many autoimmune diseases like MS, rheumatoid arthritis, or systemic lupus erythematosus. Depletion of B cells with anti-CD20 antibodies is an established therapy for MS. However, total B-cell depletion will also affect regulatory B cells that are known to suppress autoimmune responses. In our studies, we describe an alternative approach based on targeting CD79b that induces only partial B-cell depletion and achieves therapeutic effects by B-cell modulation. Prophylactic and therapeutic treatment with an antibody against CD79b and also a deglycosylated variant of this antibody, lacking effector function like antibody-dependent cellular cytotoxicity or complement activation, significantly reduced the development and progression of EAE in mice. Our data show that modulation of B cells via CD79b is equally effective as almost complete B-cell depletion with anti-CD20 antibodies and may constitute an alternative approach to treat MS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available